Regeneron Pharmaceuticals REGN Dupixent Secures FDA Approval as First Biologic for Pediatric Chronic Spontaneous Urticaria Expanding Blockbuster Drugs Addressable Market Market Moves Tech outpaces consumer sectors in mild downbeat trading JKS JinkoSolar shares climb 1085 percent despite steep Q4 2025 EPS miss and 223 percent yearoveryear revenue drop HighProfile Public Figure Defamation Litigation Media Sector Legal Risk Reputational Governance Implications